Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mannaerts, B.
Right arrow Articles by Gordon, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mannaerts, B.
Right arrow Articles by Gordon, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 15, No. 9, 1882-1883, September 2000
© 2000 European Society of Human Reproduction and Embryology

Debates Continued

Embryo implantation and GnRH antagonists

GnRH antagonists do not activate the GnRH receptor

Bernadette Mannaerts1,3 and Keith Gordon2

1 Organon, Oss, The Netherlands and 2 Organon Inc., West Orange, USA

Abstract

Recent suggestions that gonadotrophin-releasing hormone (GnRH) antagonists activate the GnRH receptor are discussed. Most of the studies cited in support of this suggestion are in-vitro studies, testing supra-pharmacological doses of GnRH analogues in cancer cell lines, whereas GnRH antagonists, e.g. ganirelix or cetrorelix, do not affect the steroidogenesis of human granulosa cells in vitro. In patients treated with GnRH antagonists prior to IVF or intracytoplasmic sperm injection (ICSI), oocyte maturity and fertilization rates are equal to those achieved following a long protocol of GnRH agonists. Although there is a tendency towards a lower pregnancy rate (not statistically significant) in the initial trials using GnRH antagonist with either recombinant FSH or human menopausal gonadotrophin (HMG) for ovarian stimulation, this new treatment option of GnRH antagonists facilitates short and simple treatment and improves the convenience and safety for the patient. As with GnRH agonists in the past, the clinical outcome of GnRH antagonist treatment will improve with time as more clinical experience is gained (learning curve) and the treatment protocol is optimized. Moreover, a GnRH agonist instead of human chorionic gonadotrophin (HCG) may be used for triggering ovulation and will decrease the cancellation rate and minimize the risk for developing ovarian hyperstimulation syndrome (OHSS).

Key words: GnRH agonist/GnRH antagonist/GnRH receptor

Notes

3 To whom correspondence should be addressed at: NV Organon PO Box 20, 5340 BH Oss, The Netherlands. E-mail: b.mannaerts{at}organon.oss.akzonobel.nl

This debate was previously published on Webtrack, June 16, 2000


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
Y. S. Choi, S.-Y. Ku, B.-C. Jee, C.-S. Suh, Y. M. Choi, J. G. Kim, S. Y. Moon, and S. H. Kim
Comparison of follicular fluid IGF-I, IGF-II, IGFBP-3, IGFBP-4 and PAPP-A concentrations and their ratios between GnRH agonist and GnRH antagonist protocols for controlled ovarian stimulation in IVF-embryo transfer patients
Hum. Reprod., August 1, 2006; 21(8): 2015 - 2021.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Mirkin, G. Nikas, J.-G. Hsiu, J. Diaz, and S. Oehninger
Gene Expression Profiles and Structural/Functional Features of the Peri-Implantation Endometrium in Natural and Gonadotropin-Stimulated Cycles
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5742 - 5752.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
H. Al-Inany and M. Aboulghar
GnRH antagonist in assisted reproduction: a Cochrane review
Hum. Reprod., April 1, 2002; 17(4): 874 - 885.
[Abstract] [Full Text]

Home page
 Hum ReprodHome page
H. Al-Innay
Subgroup analyses in Orgalutran trials
Hum. Reprod., December 1, 2001; 16(12): 2726 - 2726.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.